Monitoring the Content of Reticulocyte Hemoglobin (CHr) as the Progression of Anemia in Nondialysis Chronic Renal Failure (CRF) Patients

References

• Eschbach, J W.; Egrie, J C.; Downing, M R.; Browne, J K.; Adamson, J W. Correction of the anemia of end stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987, 316, 73–78. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Evans, R W.; Rader, B.; Manninen, D L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990, 263, 825–830. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Frankenfield, D.; Johnson, C A.; Wish, J B.; Rocco, M V.; Madore, F.; Owen, W F. Anemia management of adult hemodialysis patients in the US: results from the 1997 ESRD Core Indicators Project. Kidney Int. 2000, 57, 578–589. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Roth, D.; Smith, R D.; Schulman, G.; Steinman, T I.; Hatch, F E.; Rudnick, M R.; Sloand, J A.; Feedman, B I.; Williams, W W.,Jr.; Shadur, C A.; Benz, R L.; Teehan, B P.; Revicki, D A.; Sarokhan, B J.; Abels, R I. Effect of recombinant erythropoietin on renal function in chronic renal failure predialysis patients. Am. J. Kidney Dis. 1994, 24, 777–784. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jungers, P.; Choukroun, G.; Oualim, Z.; Robino, C.; Nguyen, A T.; Man, N K. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol. Dial. Transplant. 2001, 16, 307–312. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Van Wyck, D B.; Stivelman, J C.; Rutz, J.; Kirlin, L F.; Katz, M A.; Ogden, D A. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int. 1989, 35, 712–771. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Macdougall, I C. Poor response to erythropoietin should be fully investigated and treated. Br. Med. J. 1995, 310, 1424–1425.
   PubMedGoogle Scholar
• Besarab, A.; Amin, N.; Ahsan, M.; Vogel, S E.; Zazuwa, G.; Frinak, S.; Zazra, J J.; Anandan, J V.; Gupta, A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol. 2000, 11, 530–538. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brugnara, C.; Hipp, M J.; Irving, P J.; Lathrop, H.; Lee, P A.; Minchello, E M.; Winkelman, J. Automated reticulocyte counting and measurement of reticulocyte cellular indices: evaluation of the Miles H*3 blood analyzer. Am. J. Clin. Pathol. 1994, 102, 623–632. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kuriyama, S.; Tomonari, H.; Yoshida, H.; Hashimoto, T.; Kawaguchi, Y.; Sakai, O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997, 77, 176–185. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. DOQI (dialysis outcomes quality initiative) clinical practice guidelines—anemia of chronic renal failure. Am. J. Kidney Dis. 1997, 30 (Suppl. 3), S194–S237.
   Google Scholar
• Astro, B C.; Muntner, P.; Levin, A.; Eustace, J A.; Coresh, J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1944). Arch. Intern. Med. 1992, 162, 1401–1408. [CROSSREF], [CSA]
   Google Scholar
• Kazmi, W H.; Kausz, A T.; Khan, S.; Abichandani, R.; Ruthazer, R.; Obrador, G T.; Pereira, B J. Anemia: an early complication of chronic renal insufficiency. Am. J. Kidney Dis. 2001, 38, 803–812. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hsu, C Y.; McCulloch, C E.; Curhan, G C. Epidemiology of anemia associated with chronic renalinsufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J. Am. Soc. Nephrol. 2002, 13, 504–510. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Jungers, P Y.; Robino, C.; Choukroung, G.; Nguyen-Khoa, T.; Massy, Z A.; Jungers, P. Incidence of anemia and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol. Dial. Transplant. 2002, 17, 1621–1627. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Madore, F.; Lowrie, E G.; Brugnara, C.; Lew, N L.; Lazarus, J M.; Bridges, K.; Owen, W F. Anemia in hemodialysis patients: variables affecting this outcome predictor. J. Am. Soc. Nephrol. 1997, 8, 1921–1929. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Van Hove, L.; Goossens, W.; Van Duppen, V.; Verwilghen, R. Reticulocyte count using thiazole orange. A flow cytometric method. Clin. Lab. Hematol. 1990, 12, 287–289. [CSA]
   PubMedGoogle Scholar
• Schaefer, R M.; Schaefer, L. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rHuEPO therapy. J. Perinat. Med. 1995, 23, 83–88. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bovy, C.; Tsobo, C.; Crapanzano, L.; Rorive, G.; Beguin, Y.; Albert, A.; Paulus, J M. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int. 1999, 56, 1113–1119. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cullen, P.; Soffker, J.; Hopfl, M.; Bremer, C.; Schlaghecken, R.; Mehrens, T.; Assmann, G.; Schaefer, R M. Hypochromic red cells and reticulocyte hemoglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic hemodialysis. Nephrol. Dial. Transplant. 1999, 14, 659–665. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Skikne, B S.; Flowers, C H.; Cook, J D. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990, 75, 1870–1876. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ferguson, B J.; Skikne, B S.; Simpson, K M.; Baynes, R D.; Cook, J D. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J. Lab. Clin. Med. 1992, 19, 385–390.
   Google Scholar
• Daschner, M.; Mehls, O.; Schaefer, F. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients. Clin. Nephrol. 1999, 52, 246–252. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Fishbane, S.; Galgano, C.; Langley, R C., Jr.; Canfield, W.; Maesaka, J K. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997, 52, 217–222. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Mittman, N.; Sreedhara, R.; Mushnick, R.; Chattopadhyay, J.; Zelmanovic, D.; Vaseghi, M.; Avram, M M. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am. J. Kidney Dis. 1997, 30, 912–922. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tsuchiya, K.; Okano, H.; Teramura, M.; Iwamoto, Y.; Yamashita, N.; Suda, A.; Shimada, K.; Nihei, H.; Ando, M. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients. Clin. Nephrol. 2003, 59, 115–123. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fishbane, S.; Lynn, R I. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin. Nephrol. 1995, 44, 238–240. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Silverberg, D S.; Iaina, A.; Peer, G.; Laplan, E.; Levi, B A.; Frank, N.; Steinbruch, S.; Blum, M. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am. J. Kidney Dis. 1996, 27, 234–238. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dahdah, K.; Patrie, J T.; Bolton, W K. Intravenous iron dextran treatment in predialysis patients with chronic renal failure. Am. J. Kidney Dis. 2000, 36, 775–782. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Vanrenterghem, Y.; Barany, P.; Mann, J F.E.; Kerr, P G.; Wilson, J.; Baker, N F.; Gray, S J. Randomized trial of Dar epoetin alfa for treatment of renal anemia at a reduced dose frequency compared trial of Dar epoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002, 62, 2167–2175. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hoen, B.; Kessler, M.; Hestin, D.; Mayeux, D. Risk factors for bacterial infections in chronic hemodialysis adult patients: a multicenter prospective survey. Nephrol. Dial. Transplant. 1995, 10, 377–382. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kletzmayr, J.; Horl, W H. Iron overload and cardiovascular complications in dialysis patients. Nephol. Dial. Transplant. 2002, 17 (Suppl. 2), 25–29. [CSA]
   PubMedGoogle Scholar